论文信息 - S4-8: First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2−positive locally recurrent/metastatic breast cancer (LR/mBC) - 字舞流文

S4-8: First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2−positive locally recurrent/metastatic breast cancer (LR/mBC)

R. Greil | F. André | V. Semiglazov | G. Romieu | A. Wardley | X. Pivot | L. Gianni | M. Lichinitser | S. Serrano | S. Chan | A. Chan | O. Lipatov | L. Provencher | A. Moliterni | M. Mansutti | I. Smirnova | N. Moore | S. Prot | A. Chan